1-(4-Phenylmethoxyphenyl)hexan-1-one | 1415596-61-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-Phenylmethoxyphenyl)hexan-1-one
• 英文别名: 1-(4-phenylmethoxyphenyl)hexan-1-one
• CAS: 1415596-61-0
• 化学式: C₁₉H₂₂O₂
• 分子量: 282.382
• InChiKey: MQEINPXAEUJELI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-Phenylmethoxyphenyl)hexan-1-one 在 偶氮二甲酸二异丙酯 、 三溴化硼 、 三苯基膦 、 copper(ll) bromide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 3-[4-[5-butyl-2-[4-(4-chlorophenoxy)phenyl]-1,3-thiazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine
  参考文献：
  名称：

  Synthesis and structure–activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer’s disease

  摘要：

  A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on A beta-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on A beta-RAGE binding. Compounds selected from A beta-RAGE binding screening displayed inhibitory activity on A beta transport across BBB. They also showed inhibitory activity against A beta-induced NF-kappa B activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.022
• 作为产物：
  描述：

  4-羟基苯甲腈 在 potassium carbonate 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 生成 1-(4-Phenylmethoxyphenyl)hexan-1-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer’s disease

  摘要：

  A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on A beta-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on A beta-RAGE binding. Compounds selected from A beta-RAGE binding screening displayed inhibitory activity on A beta transport across BBB. They also showed inhibitory activity against A beta-induced NF-kappa B activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.022

文献信息

• Synthesis and structure–activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer’s disease
  作者：Yun Suk Lee、Hee Kim、Young-Ho Kim、Eun Joo Roh、Hogyu Han、Kye Jung Shin

  DOI：10.1016/j.bmcl.2012.10.022

  日期：2012.12

  A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on A beta-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on A beta-RAGE binding. Compounds selected from A beta-RAGE binding screening displayed inhibitory activity on A beta transport across BBB. They also showed inhibitory activity against A beta-induced NF-kappa B activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD. (C) 2012 Elsevier Ltd. All rights reserved.